StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of Galmed Pharmaceuticals stock opened at $0.39 on Wednesday. The company’s 50-day moving average price is $0.36 and its two-hundred day moving average price is $0.38. The stock has a market cap of $1.98 million, a PE ratio of -0.12 and a beta of 0.87. Galmed Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its quarterly earnings data on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- How to Read Stock Charts for Beginners
- MarketBeat Week in Review – 4/22 – 4/26
- What is the FTSE 100 index?
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Monster Growth Stocks to Buy Now
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
